We are excited to announce that we are an early investor and partner in Artera, a company that is developing multimodal artificial intelligence-based predictive and prognostic cancer tests. We believe that Artera has the potential to revolutionize the way cancer is treated, and we are proud to have been a part of their journey since 2021.

Artera's flagship test is the ArteraAI Prostate Test, the first test to predict therapy benefit in localized prostate cancer. The test uses machine learning to analyze digital pathology images and clinical data to predict whether a patient will benefit from hormone therapy and estimate their long-term outcomes. This information can help doctors make more informed treatment decisions for their patients, leading to better outcomes.

The $90 million in funding that Artera has raised will be used to distribute the ArteraAI Prostate Test in the U.S. and internationally, and to develop tests to support therapy personalization in other cancers. We are confident that Artera will make significant progress in the coming years, and we are excited to see what they accomplish.

We were first introduced to Artera in 2021, and we were immediately impressed with the team and their technology. The Artera team is composed of world-renowned experts in cancer biology, artificial intelligence, and clinical diagnostics. They have a deep understanding of the challenges in cancer care, and they are passionate about using their technology to make a difference in the lives of cancer patients.

We were also impressed with Artera's technology. The ArteraAI Prostate Test is the first test to use multimodal artificial intelligence to predict therapy benefit in localized prostate cancer. This is a significant advance, as it provides doctors with more information to make informed treatment decisions.

We have been impressed with Artera's progress since we first invested in them. They have quickly built a strong team, developed a cutting-edge product, and made significant progress in the regulatory process. We are confident that Artera will continue to be a leader in the field of personalized cancer care.

We are proud to have been an early investor in Artera, and we look forward to continuing to support them on their journey to revolutionize cancer care.

We are excited about Artera because of the following reasons:

• They have a strong team with a deep understanding of cancer biology and artificial intelligence.
• They are developing cutting-edge AI technology that has the potential to revolutionize cancer care.
• They are committed to making their products accessible to all patients, regardless of their financial means.
• They have a clear vision for the future of personalized cancer care.

We are excited to see what Artera accomplishes in the years to come.